Human fetal mesencephalic tissue can be successfully used in dopamine (DA) cell replacement therapy in Parkinsons disease (PD), nevertheless, further advances have been impeded due to limited tissue availability. Stem cell-based approaches have received much hype as potential treatments for neurodegenerative disorders, but have shown poor cell survival. The brains of three patients with Parkinsons disease who had undergone transplants of fetal tissue were examined postmortem and it was observed that some transplanted cells contained clumps of protein containing alpha-synuclein. Inducible pluripotent stem (iPS) cells derived from somatic cells and human embryonic stem cells, represent a novel renewable source of tissue precursors and therapeutic safety necessitate much more in-depth research before the initiation of human clinical trials.
Keywords: Parkinson's disease, neural stem cells, replacement therapy, induction of pluripotent stem cells, Stem Cells, therapy in Parkinson's disease, neurodegenerative disorders, Inducible pluripotent stem (iPS) cells, neural transplantation, somatic cells and human embryonic stem cells, embryonic stem cells, Stem Cell, –, Based Regeneration, Human ES cell-derived dopaminergic neurons, cell therapy in neurodegenerative diseases, neural stem cells in Parkinson's disease, Gene therapy, Regeneration-based therapies, embryonic germ cells, epigenetic reprogramming, Stem Cell Research, stem cell-specific expertise, human embryonic pluripotent stem cells, adult stem cells, stem cell-based therapies, progenitor cell transplants, Transplanted dopaminergic
Rights & PermissionsPrintExport